Can Congress Save the $28 Billion Hemp Market From Itself?

Congress is facing a self-inflicted crisis that could destabilize a $28 billion hemp marketplace in the span of a few months. At the center of this brewing catastrophe is a hidden provision buried in an agriculture appropriations measure that almost no one paid attention to when it passed, but which threatens to upend an entire industry built over the last seven years.

The provision is Section 781 of the Consolidated Appropriations and Education Act (CAEA), and it takes effect November 12, 2026. The stakes couldn't be higher, the timeline is rapidly tightening, and Congress now faces a genuine policy challenge of its own making. Two Democratic senators—Oregon's Ron Wyden and Jeff Merkley—have introduced the Cannabinoid Safety and Regulation Act (CSRA) as an emergency measure to prevent catastrophic market disruption.

Meanwhile, Representative Gregory Baird has offered an alternative via the Hemp Planting Predictability Act (H.R. 7024) that would delay implementation.

Understanding what's happening, why it matters, and what Congress is actually debating requires unpacking complex definitional and regulatory issues that don't fit neatly into headlines. But the outcome will have concrete consequences for thousands of hemp farmers, manufacturers, retailers, and millions of consumers dependent on hemp-derived cannabinoid products.

The Definition Problem: How a Technicality Could Destroy a Market
The Scale of the Problem: A $28 Billion Threat
The CSRA: Wyden and Merkley's Emergency Intervention
The Merkley Alternative: Buy Time to Get it Right
The Broader 2026 Farm Bill: Deregulation Meets Restriction
What Industry Really Needs: Clarity and Stability
Industry Perspectives: Divided but Urgent
The Timeline: Months Remaining for Congressional Action
Conclusion: Congress Must Fix Its Own Mistake

The Definition Problem: How a Technicality Could Destroy a Market

The 2018 Farm Bill [Quick Definition: The federal law that legalized hemp with less than 0.3% THC, creating the hemp CBD industry], which legalized industrial hemp, defined legal hemp as cannabis plants containing no more than 0.3% delta-9 [Quick Definition: The primary psychoactive compound in cannabis] tetrahydrocannabinol (THC) by dry weight. This single percentage threshold opened the entire industry because it allowed farmers to cultivate hemp with minimal federal restriction and minimal regulatory burden. That straightforward definition has been the industry's foundational assumption for seven years.

Then Congress did something that almost no one in the hemp industry paid careful attention to: it included Section 781 in an agriculture appropriations measure. This section fundamentally redefines legal hemp. Instead of measuring only delta-9 THC content, Section 781 redefines hemp by its total THC content.

On the surface, this might sound like a technical adjustment, a clarification improving regulatory clarity. In reality, it's a seismic shift with potentially catastrophic consequences. Here's why: When hemp-derived cannabinoids like delta-8 THC or delta-10 [Quick Definition: A rare hemp-derived THC isomer with mild psychoactive effects] THC are processed from CBD isolate, those conversion processes necessarily produce byproducts and minor cannabinoid residues that technically include some delta-9 THC.

Similarly, many hemp plants naturally contain small amounts of delta-9 THC along with delta-8, delta-10, CBN, and other cannabinoids.

Under the current definition (delta-9 THC only), these products are legal if delta-9 levels remain below 0.3%. Under the new definition (total THC), these same products would instantly become illegal because total THC content exceeds the threshold. Manufacturers producing delta-8 gummies, delta-10 edibles, hemp-derived CBN products, and countless other items would suddenly violate federal law, even though they're complying with current regulations.

The Scale of the Problem: A $28 Billion Threat

The hemp market has grown explosively over the past five years, driven largely by consumer interest in cannabinoids beyond conventional CBD. While CBD edibles and tinctures remain popular, the faster-growing segments involve delta-8, delta-10, CBN, and other minor cannabinoids. These products were estimated to generate approximately $10-12 billion in retail sales in 2025 and are projected to expand significantly through 2026.

When Section 781 takes effect November 12, 2026, the legal status of these products becomes ambiguous at best, unlawful at worst. This doesn't just threaten retailers and manufacturers; it threatens the entire infrastructure supporting the legal hemp market. Distributors would face liability for transporting products that might be illegal.

Banks would face regulatory pressure to terminate accounts for hemp businesses. Farmers investing in crops optimized for cannabinoid conversion would face harvest losses.

The uncertainty alone is already creating market instability. Savvy investors are positioning to capitalize on potential disruption. Some retailers are attempting to clear inventory before November 12.

Manufacturers are reconsidering product development. Farmers are delaying planting decisions. A $28 billion market is beginning to exhibit stress signals almost a year before the regulatory change is supposed to take effect.

The CSRA: Wyden and Merkley's Emergency Intervention

Recognizing the imminent crisis, Senators Ron Wyden and Jeff Merkley of Oregon—a state with significant hemp cultivation and processing industry—introduced the Cannabinoid Safety and Regulation Act. Their approach preserves the current delta-9 THC definition, maintaining the legal status of existing hemp-derived cannabinoid products while creating a new regulatory framework to address legitimate safety and consumer protection concerns.

The CSRA takes a sophisticated approach to the underlying policy challenge: Congress actually shouldn't have sneaked a major market-altering regulation into an appropriations bill without industry input or public debate. But now that Section 781 exists and creates policy uncertainty, Congress should fix the mess through explicit, transparent legislation.

Wyden and Merkley's bill essentially says: "We're going to keep hemp legal as currently defined (delta-9 THC below 0.3%), but we're going to implement meaningful safety standards that address real concerns about product quality, labeling, and consumer protection." The CSRA establishes federal guidelines for cannabinoid products, requiring accurate labeling, testing standards, and traceability. It creates explicit authority for the FDA and USDA to develop regulations addressing safety, quality, and consumer protection—the regulatory goals that Section 781 was theoretically attempting to achieve, but through a much more rational, evidence-based process.

From a policy perspective, this is actually elegant. Rather than crudely redefining hemp in ways that destroy existing legal markets without addressing actual safety concerns, the CSRA creates regulatory infrastructure that can evolve as science and industry practices evolve. It's the approach that should have been taken from the beginning.

The Merkley Alternative: Buy Time to Get it Right

Representative Gregory Baird introduced the Hemp Planting Predictability Act (H.R. 7024) as an alternative approach. Rather than changing Section 781, this bill would delay its implementation by three years—pushing the effective date from November 12, 2026 to November 12, 2029. This gives the industry, Congress, and regulators time to develop comprehensive regulations addressing legitimate safety concerns without instantly destroying existing legal markets.

The delay approach has merit if Congress believes it needs more time to develop comprehensive cannabinoid regulations. Three additional years would allow:

Scientific research on minor cannabinoid safety and efficacy to mature
Industry consolidation around best practices for quality control and testing
Regulators to develop evidence-based standards rather than reactive prohibitions
Farmers to adjust crop planning and investment strategies
Manufacturers to develop compliant product formulations and supply chains

However, the delay approach also has downsides. It maintains uncertainty during the three-year interim period. Manufacturers, retailers, and investors remain unsure whether Section 781 will actually take effect, whether it will be modified, or whether further delays are coming.

Some would argue that additional years of uncertainty is nearly as harmful as immediate implementation.

The Broader 2026 Farm Bill: Deregulation Meets Restriction

Complicating this landscape further is the 2026 Farm Bill, which is currently being drafted. The 802-page bill (H.R. 7567) contains several provisions relevant to hemp regulation, generally aimed at reducing regulatory burdens on farmers and small operators. These deregulatory provisions exist in tension with the CAEA's more restrictive definitional changes.

This creates an awkward policy moment where Congress is simultaneously moving in two opposite directions. The Farm Bill aims to reduce testing requirements and regulatory burdens for industrial hemp farmers. Meanwhile, the CAEA/Section 781 is attempting to restrict which cannabinoid products can be legally produced.

These conflicting impulses haven't been reconciled.

What Industry Really Needs: Clarity and Stability

Beneath all the legislative maneuvering is a straightforward industry need: clarity and stability. Farmers, manufacturers, retailers, and consumers all need to understand the legal status of hemp-derived cannabinoid products beyond 2026. Currently, they don't.

This uncertainty is already creating market distortions and reducing investment in what would otherwise be a thriving sector.

The ideal resolution would involve Congress making a deliberate choice about hemp policy rather than allowing major market-altering regulations to be buried in appropriations bills. If Congress wants to maintain a legal hemp market for cannabinoid products, it should say so explicitly and create appropriate regulatory frameworks. If Congress wants to restrict or prohibit certain cannabinoid products, it should also say so explicitly, with appropriate transition periods and regulatory guidance.

What Congress shouldn't do—and what it appears to have done through Section 781—is allow catastrophic policy changes to take effect through legislative opacity and inattention.

Industry Perspectives: Divided but Urgent

The hemp industry itself is somewhat divided on optimal policy approaches. Larger, more established companies with capital resources to navigate regulatory complexity often favor CSRA-style regulation that creates clear rules they can comply with through investment in quality control, testing, and compliance infrastructure. Smaller manufacturers and retailers, operating on thinner margins, sometimes view additional regulation as a cost they can't absorb, making H.R. 7024's delay approach more appealing.

Consumer advocacy groups are broadly supportive of genuine safety standards while opposed to prohibition-style restrictions that eliminate legal access to products many consumers find valuable. The broader theme uniting these constituencies is support for the CSRA's approach: explicit, transparent regulation setting safety standards while maintaining market access.

The Timeline: Months Remaining for Congressional Action

This is the critical detail driving urgency: Section 781 takes effect November 12, 2026. It's currently March 25, 2026. Congress has approximately seven-and-a-half months to either pass the CSRA, pass the Hemp Planting Predictability Act, incorporate relevant provisions into the Farm Bill, or do nothing (in which case Section 781 takes effect and hemp-derived cannabinoid markets face immediate crisis).

Given congressional calendars, election-year politics, and the general pace of legislative action, the timeline is extremely tight. If comprehensive legislation doesn't pass relatively quickly, the market faces November 12 with unresolved regulatory ambiguity.

Conclusion: Congress Must Fix Its Own Mistake

Congress faces a genuine policy challenge of its own creation. By including Section 781 in an appropriations bill without adequate industry input or public debate, it set the stage for a $28 billion market disruption. Now it must decide whether to prevent that disruption through explicit regulatory clarity.

The CSRA offers a rational approach: preserve current hemp market legality while implementing genuine safety standards through transparent regulatory processes. The Hemp Planting Predictability Act offers a pragmatic alternative: buy time to develop comprehensive regulations. Either approach beats allowing the current Section 781 language to take effect without modification.

The hemp industry is watching intently. The clock is ticking toward November. Congress must act.

Pull-Quote Suggestions:

"Congress is facing a self-inflicted crisis that could destabilize a $28 billion hemp marketplace in the span of a few months."

"A $28 billion market is beginning to exhibit stress signals almost a year before the regulatory change is supposed to take effect."

"These products were estimated to generate approximately $10-12 billion in retail sales in 2025 and are projected to expand significantly through 2026."

Why It Matters: Senators Wyden and Merkley introduced the CSRA to preserve the $28B hemp market before Section 781 takes effect. Here's what's at stake for the industry.